SynthesisPloS one2018
Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Research mapping and comparative assessment of drug treatment regimens for brucellosis: a systematic review and network meta-analysis.BMC infectious diseases · 2025Pooled it
- Updated therapeutic options for human brucellosis: A systematic review and network meta-analysis of randomized controlled trials.PLoS neglected tropical diseases · 2024Pooled it
- Efficacy and safety of therapeutic strategies for human brucellosis: A systematic review and network meta-analysis.PLoS neglected tropical diseases · 2024Pooled it
- CueO Possesses Copper Detoxification Activity Linking Bacterial Virulence and Drug Resistance in Brucella.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Brucellosis Surveillance - United States, 2010-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026Article
- Epidemiological features of brucellosis and factors affecting its treatment failure and relapse in Qom Province, Iran.Ghana medical journal · 2021Article
- Protein Biomarker Identification for the Discrimination ofFrontiers in microbiology · 2021Article
- β-Sitosterol Contributes in the Resistance to Invasion and Survival ofJournal of microbiology and biotechnology · 2020Article
- An Overview of Brucellosis in Cattle and Humans, and its Serological and Molecular Diagnosis in Control Strategies.Tropical medicine and infectious disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucellosis is a zoonotic disease with a high morbidity in developing countries, but there the optimal treatment is not yet determined. Therefore, the development of a simple and effective treatment is important. The aim of this study was to summarize the available evidences and compare rifampicin with streptomycin in human brucellosis with doxycycline as background regimen. We systematically searched PubMed, EmBase, and the Cochrane Library from their inception up through December 2016. We included studies with a randomized controlled design that evaluated the effect of streptomycin compared with rifampicin in human brucellosis patients who received doxycycline therapy as background regimen. The overall failure and relapse were summarized using random-effects model. Our meta-analysis included 1,383 patients with brucellosis from 14 trials. We found that patients who received rifampicin therapy had a higher risk of overall failure (RR: 2.36; 95% CI: 1.72-3.23; P<0.001) and relapse (RR: 2.74; 95% CI: 1.80-4.19; P<0.001) compared with streptomycin. Results of the sensitivity analysis were consistent with the overall analysis. Subgroup analysis indicated that mean age of the patients and percentage of male participants might influence the treatment effects. Furthermore, no publication bias was detected. The findings of this study indicated that rifampicin therapy significantly increased the risk of overall failure and relapse compared with streptomycin. Hence, it can be recommended to patients with human brucellosis receiving streptomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.